Dr. Don O. Kikkawa, MD

Dr. Kikkawa practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Kikkawa's NPI, 1932202371, was assigned on September 7, 2006. Dr. Kikkawa graduated from Saint Louis University School Of Medicine in 1987. Dr. Kikkawa holds California license G65447.

Dr. Kikkawa's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Kikkawa's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Kikkawa is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Kikkawa to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kikkawa practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Kikkawa's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Kikkawa is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Kikkawa's licenses on file in 2 states: California and Wisconsin.

Dmand AI lists conjunctivitis, dry eye, eyelid inflammation, vision problems and visual impairment and blindness among the conditions Dr. Kikkawa treats.

CMS data shows 6,478 Medicare services from Dr. Kikkawa across 20 procedure codes in 2024, for 544 Medicare patients. Medicare paid $219,316 for them.

CMS counts 544 Medicare patients who saw Dr. Kikkawa in 2024. The largest group is 65 to 74, with 253 patients. 75% of them have high cholesterol, and 62% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.09, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kikkawa's median patient age at 63, with 67% women.

In 2024, Dr. Kikkawa wrote 225 Medicare Part D claims for 147 patients. 56% of them were for generic drugs. CMS names the drug for 141 of them, across 3 drugs with 11 or more claims each, at $2,628 in total drug cost. In 2023, CMS named 158 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Kikkawa for performance year 2024, reported as part of a group. Dr. Kikkawa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kikkawa as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 211 papers to Dr. Kikkawa, published from 2002 to 2025. 2024 was the busiest year, with 18. The most frequent topics are Graves Ophthalmopathy, Orbit and Eyelids. Dr. Kikkawa has published most often in Ophthalmic Plast Reconstr Surg. Dr. Kikkawa's most frequent co-authors are Bobby S. Korn, MD, David B. Granet, MD and Audrey C. Ko, MD.

Dmand AI links Dr. Kikkawa to 1 clinical trial.

CMS Open Payments shows 239 general payments to Dr. Kikkawa from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Amgen Inc. paid the most, $214,997.

Dmand AI lists 8 awards for Dr. Kikkawa, most recently Best Doctors in America in 2015.

Dr. Kikkawa graduated from Saint Louis University School Of Medicine in 1987. Dr. Kikkawa is a member of ACS.

Dr. Kikkawa is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.